Moreover, researchers have engineered NKCE to simultaneously engage NK cells through Siglec-7 and OC targets through FSHR, which is specific to its target cells and is potent in killing tumor cells, as evaluated using a panel of different human ovarian tumor cell lines (110). This evidence concerns the gene BGLAP and ovarian neoplasm.